+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 288 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are studying a new vaccine called V118C to help prevent pneumococcal disease, which is caused by Streptococcus pneumoniae bacteria and can lead to infections in the lungs or other parts of the body. This trial focuses on toddlers and infants to evaluate the safety and tolerability of V118C. The study is a Phase 1, randomized, double-blind trial comparing V118C with an existing pneumococcal vaccine called PCV20 in children. The study has two stages. Stage 1 includes toddlers aged 12 to 15 months who have completed a 3-dose infant series of PCV20 these participants receive a single 0.5 mL injection of either V118C or PCV20. Stage 2 enrolls infants around 2 months old who receive four doses of either V118C or PCV20 at 2, 4, 6, and 12 months of age. All doses are given by intramuscular injection. The study monitors participants in both stages for up to 12 months after vaccination. During the trial, researchers will track immediate and longer-term side effects, both at the injection site and systemically, for up to one year post-vaccination. They will also measure immune responses using blood tests to assess antibody levels against pneumococcal bacteria. Participants will have scheduled visits for vaccinations and follow-up assessments to evaluate safety, immune response, and tolerability of the vaccines over the study period.

Age: 2Months - 15MonthsAll GendersPhase 1
15 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
W

Actively Recruiting

Researchers are evaluating a culturally-tailored home-based physical activity program designed for Hispanic or LatinoLatina adolescent and young adult childhood cancer survivors. These survivors may face long-term effects like weight gain, fatigue, and reduced physical fitness after cancer treatment. The study aims to see if this culturally-relevant program can help increase physical activity and improve overall health compared to using a Fitbit tracker alone. The study has two stages. In Stage 1, 20 Latinx survivors participate in developing the intervention using Fitbit trackers, text messages, social media support, wearable activity devices, and interviews over 9 months. In Stage 2, 170 survivors who do not meet physical activity guidelines are randomized to either the intervention group, which includes Fitbit use, weekly goal-setting, peer support via social media and Zoom meetings, and optional activity partners, or a control group that only uses Fitbit trackers for 12 weeks. The intervention includes an intensive phase with weekly sessions followed by a 4-week maintenance phase. Participants will wear Fitbit trackers daily and engage in goal-setting, peer discussions, and physical activity reminders. Researchers will measure moderate to vigorous physical activity, sedentary time, and health-related quality of life over 12 weeks. Additional evaluations include physiological markers of heart and metabolic health and qualitative interviews to improve the program. The study lasts through the intervention phases with ongoing monitoring and support for participants.

Age: 15Years - 20YearsAll GendersPhase 2
77 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of abrocitinib oral suspension, with or without topical medications, in children aged 2 years and older who have moderate-to-severe atopic dermatitis. This Phase 3 open-label study includes two groups children who previously completed abrocitinib studies and those who have never participated in such studies. The study aims to better understand the treatments impact over an extended period. Participants will receive abrocitinib oral suspension throughout the study, which may last up to 24 months or until the medicine becomes commercially available, whichever happens first. The study will enroll up to 500 children globally, split between those continuing from previous trials and new participants aged 6 to under 12 years. All children will receive the same study treatment during this period. Throughout the study, participants will be closely monitored with regular assessments of safety, including treatment-related side effects and laboratory tests. Researchers will also evaluate skin condition improvements using various scales and indexes, itch intensity, quality of life measures, and the need for additional topical treatments. This comprehensive follow-up will last up to two years to track long-term effects and safety outcomes.

Age: 2Years - 11YearsAll GendersPhase 3
39 locations
M

Actively Recruiting

Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.

Age: 18Years - 75YearsAll GendersPhase 2
57 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of a peer recovery coaching intervention called RC-Link for patients hospitalized due to medical complications from Alcohol Use Disorder AUD. This study aims to improve recovery outcomes by reducing heavy drinking, enhancing biopsychosocial functioning, and achieving remission from AUD, guided by the new NIAAA definition of recovery. The study will also explore mechanisms behind heavy drinking using daily ecological momentary assessment EMA and assess the cost-effectiveness of the RC-Link program through a randomized controlled trial design. The trial compares two groups one receiving bedside peer recovery coaching initiated during hospitalization plus six months of ongoing support, and a control group receiving a brief intervention, usual care with a referral list, and follow-up contact after the study period. The RC-Link program involves personalized recovery planning with a peer coach and regular contact at least twice a week via phone, virtual, or in-person meetings, using a standardized coaching checklist to provide socioemotional, instrumental, and informational support. Participants will be assessed at baseline, monthly during the six-month intervention, and six months after intervention completion. Evaluations include heavy drinking frequency, remission status based on DSM-5 criteria, biopsychosocial functioning, cost-effectiveness, coping, treatment and social support engagement, hospital utilization, breath alcohol content levels, and craving changes. This comprehensive monitoring aims to understand how peer recovery coaching affects long-term recovery outcomes for hospitalized AUD patients.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are conducting a Phase 1, open-label study to evaluate CTX-10726, a new drug given alone to patients with advanced or metastatic cancers including gastroesophageal cancer, hepatocellular carcinoma, endometrial cancer, and renal cell carcinoma. The main goals are to assess the safety, tolerability, immune response, and how the drug moves through the body. The study also looks at early anti-tumor activity to understand its potential effects. Participants receive CTX-10726 through intravenous infusion every two weeks. The study has two parts a Dose Escalation Cohort where different dose levels 0.3 to 10.0 mgkg are tested to identify safe doses, followed by a Dose Expansion Cohort where selected doses from the first part are further evaluated. The Dose Escalation uses a 33 design, and dosing continues with regular infusions during the treatment periods. During the study, participants undergo regular monitoring for side effects and drug effects, including blood tests and imaging to measure tumor response. Researchers measure drug levels in the blood and immune responses. Safety is tracked from the first dose until 30 days after the last dose, with some participants monitored for up to two years. The study includes assessments of tumor size, duration of response, disease control, survival, and detailed pharmacokinetic measurements.

Age: 18Years +All GendersPhase 1
8 locations
P

Actively Recruiting

Researchers are evaluating KK2430, an experimental intravenous drug, as a potential treatment for people with Hematologic Neoplasms. This Phase 12 study aims to understand whether KK2430 is safe, how the body processes it, and whether it shows any effects in treating this condition. KK2430 has not been previously approved by health authorities, and this study marks its first use in humans. Participants will receive KK2430 through intravenous administration, with some possibly receiving a placebo as part of the study design. The study is conducted in a sequential manner, focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. The study includes a treatment period lasting an average of three months, during which various assessments will be made. Throughout the study, participants will undergo multiple evaluations including dose level toxicity checks 28 days after the first dose and monitoring of adverse events for about 1.5 years. Other assessments during treatment include pregnancy tests, ECG measurements of QT and QRS intervals, and vital sign monitoring. Participants will be followed from screening through study completion to collect safety and effectiveness data, with the total study period lasting until around October 2027.

Age: 18Years +All GendersPhase 1Phase 2
1 location
P

Actively Recruiting

Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.

Age: 18Years +All GendersPhase 1Phase 2
107 locations
P

Actively Recruiting

Researchers are evaluating multiple investigational therapies in adult participants with moderately to severely active Crohns Disease or Ulcerative Colitis, which are types of Inflammatory Bowel Disease IBD. This Phase 2 platform study aims to assess the safety, effectiveness, how the body processes the drugs, and their effects on the disease. The study is sponsored by Mirador Therapeutics, Inc. and is designed to explore several oral or intravenous experimental treatments. Participants will be assigned to receive one of several treatments including MT-501 tablets or multiple intravenous doses of MT-201 combined with standard care. Different groups will receive these therapies to compare their effects. The treatment period lasts up to 13 weeks, during which participants will be closely monitored for responses and side effects. During the study, participants will undergo assessments including endoscopy and clinical evaluations to measure disease activity and response. Laboratory tests will monitor safety, and pharmacokinetics will track how the drugs are absorbed and processed. Researchers will observe treatment side effects and disease improvement using specific clinical and endoscopic measures over 12 to 13 weeks. The total participation duration corresponds to the treatment and monitoring period outlined.

Age: 18Years - 80YearsAll GendersPhase 2
66 locations

1-10 of 288

1